GlaxoSmithKline (GSK) has submitted asthma candidate mepolizumab in Europe and the US, taking a lead in the race to bring an interleukin-5 (IL-5) antagonist to market. Mepolizumab has been submitted ...

Sputum neutrophil percentage and levels of eotaxin-1, IL-5 and eosinophil peroxidase may be used to predict remission among patients with severe asthma 1 year after anti-IL-5 therapy, according to ...

It is a humanized anti-IL5 antibody that blocks the binding of IL5 to its receptor's alpha chain. It was approved by the FDA on Nov. 4, 2015, for patients with asthma age >12 and serum eos >150/ul.

The medicine has a pretty restrictive label, which gives it an addressable market of 300,000 to 400,000 patients. Nucala was approved as an add-on maintenance treatment for severe asthma in ...

Are next-generation anti-IL5 mAbs set to change the course of the severe asthma treatment market, or will it be Regeneron/Sanofi's anti-IL-4/IL-13 mAb, dupilumab?

For this study, researchers used a recent Cochrane review on anti-IL5 treatments as well as additional studies involving patients ≥12 years with severe asthma treated with anti-IL5 therapy.

GSK receives positive CHMP opinion in Europe for novel anti-IL5 biological Nucala (mepolizumab) for the treatment of patients with severe refractory eosinophilic asthma Sep 24, 2015 10:20am Pharma ...

What targets do anti–IL-5 therapies address that other treatments do not? So the anti–IL-5 therapies, as I've mentioned, have been really life-changing for some patients with eosinophilic asthma.

By John CarrollOct 9, 2014 10:38am Clinical Data AstraZeneca's headquarters in London--Courtesy of AstraZeneca ...

News Published: 07 November 2014 Anti-IL-5 biologics carve out severe-asthma niche Elie Dolgin Nature Biotechnology 32, 1075–1076 (2014) Cite this article ...

GSK’294 is an anti-IL-5 monoclonal antibody currently in development for the treatment of severe eosinophilic asthma. It is a distinct, new biologic entity and has been engineered for high affinity ...